IFRX
InflaRx NV
NASDAQ · Healthcare · Biotechnology · DE
$2.09
+1.46%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +13.3%
- EBIT
- +28.2%
- EPS
- +31.8%
- Free cash flow
- +44.5%
- Operating cash flow
- +44.7%
Forward estimates
Based on analyst estimates
- Revenue
- +202.5%
- EBITDA
- +66.1%
- EPS
- +46.3%
Three-year CAGR
- Revenue
- -31.8%
- EBITDA
- +0.9%
- EBIT
- +8.8%
- Net income
- +0.9%
- EPS
- +15.4%
- Free cash flow
- +30.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026